• Explore /
  • Poster
  • / NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

Abstract Poster

Authors

Mairead McNamara

Mairead Geraldine McNamara

University of Manchester/The Christie, Manchester, United Kingdom;

Mairead Geraldine McNamara , Jayne Swain , Zoe Craig , Rohini Sharma , Olusola Olusesan Faluyi , Jonathan Wadsley , Carys Morgan , Lucy R. Wall , Ian Chau , Nick Reed , Debashis Sarker , Jane Margetts , Daniel Krell , Judith Cave , Sothi Sharmila , Alan Anthoney , Alkesh Patel , Angela Lamarca , Richard Hubner , Juan W. Valle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03837977

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 646)

DOI

10.1200/JCO.2023.41.4_suppl.646

Abstract #

646

Poster Bd #

G15

Abstract Disclosures

Similar Posters

First Author: Mairead Geraldine McNamara

First Author: Zoe Craig

First Author: Thomas Jens Ettrich

First Author: Thomas Jens Ettrich